Anemia Drugs May Not Be Safe At Low Levels: FDA

Law360, New York (November 9, 2007, 12:00 AM EST) -- The Food and Drug Administration has toughened its black-box warnings on three Amgen Inc. anemia drugs, warning patients that not only could high doses of the drug increase their risk of death but also that relatively low doses were not necessarily safe either.

The target drugs, erythropoiesis-stimulating agents Aransep, Epogen and Procrit, were first slapped with the black-box warning—the FDA's strongest—in March.

All three drugs are taken by anemic patients with chronic kidney failure as well as cancer patients whose chemotherapy triggered anemia, although the latter...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.